Maxcyte (MXCT) Total Non-Current Liabilities (2020 - 2026)

Maxcyte has reported Total Non-Current Liabilities over the past 6 years, most recently at $30.8 million for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 6.65% to $30.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.8 million through Dec 2025, down 6.65% year-over-year, with the annual reading at $30.8 million for FY2025, 6.65% down from the prior year.
  • Total Non-Current Liabilities was $30.8 million for Q4 2025 at Maxcyte, down from $33.2 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $35.8 million in Q4 2023 and troughed at $13.1 million in Q3 2021.
  • The 5-year median for Total Non-Current Liabilities is $31.0 million (2024), against an average of $28.9 million.
  • Year-over-year, Total Non-Current Liabilities soared 144.74% in 2022 and then dropped 10.1% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $20.8 million in 2021, then soared by 50.99% to $31.4 million in 2022, then increased by 14.22% to $35.8 million in 2023, then fell by 8.04% to $32.9 million in 2024, then fell by 6.65% to $30.8 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Total Non-Current Liabilities are $30.8 million (Q4 2025), $33.2 million (Q3 2025), and $28.8 million (Q2 2025).